Aerovate Therapeutics (NASDAQ:AVTE) Announces Earnings Results, Beats Estimates By $0.03 EPS

Aerovate Therapeutics (NASDAQ:AVTE) announced its quarterly earnings data on Tuesday. The company reported ($0.56) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.03, Zacks reports.

Aerovate Therapeutics Stock Down 2.7 %

Shares of AVTE stock opened at $2.56 on Friday. The business’s fifty day moving average price is $2.20 and its 200 day moving average price is $6.31. Aerovate Therapeutics has a 1-year low of $1.25 and a 1-year high of $32.42.

About Aerovate Therapeutics

Aerovate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.